A Phase 1, Open-Label Study to Characterize the Pharmacokinetics and Safety of a Single Oral Dose of GBT440 in Subjects With Hepatic Impairment

Next Previous
Trial Profile

A Phase 1, Open-Label Study to Characterize the Pharmacokinetics and Safety of a Single Oral Dose of GBT440 in Subjects With Hepatic Impairment

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2018

At a glance

  • Drugs Voxelotor (Primary)
  • Indications Liver disorders
  • Focus Pharmacokinetics
  • Sponsors Global Blood Therapeutics

    • Most Recent Events

    • 20 Feb 2018 Planned End Date changed from 1 Nov 2017 to 8 Mar 2018.
    • 20 Feb 2018 Planned primary completion date changed from 1 Nov 2017 to 21 Feb 2018.
    • 20 Feb 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top